PDS Biotechnology Co. (NASDAQ:PDSB) Shares Purchased by XTX Topco Ltd

XTX Topco Ltd increased its stake in shares of PDS Biotechnology Co. (NASDAQ:PDSB) by 241.8% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 67,182 shares of the company’s stock after purchasing an additional 47,528 shares during the period. XTX Topco Ltd owned approximately 0.18% of PDS Biotechnology worth $257,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PDSB. Tempus Wealth Planning LLC purchased a new position in shares of PDS Biotechnology during the second quarter worth $55,000. Ground Swell Capital LLC purchased a new position in PDS Biotechnology during the 2nd quarter valued at about $67,000. Blair William & Co. IL grew its position in PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after acquiring an additional 81,743 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of PDS Biotechnology during the second quarter worth about $146,000. Finally, Squarepoint Ops LLC purchased a new position in shares of PDS Biotechnology in the second quarter valued at approximately $120,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PDSB. B. Riley cut their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, November 25th. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, PDS Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $11.67.

PDS Biotechnology Stock Performance

Shares of PDSB stock opened at $1.81 on Thursday. The company has a market cap of $67.52 million, a P/E ratio of -1.56 and a beta of 1.85. The firm has a fifty day moving average price of $2.64 and a 200 day moving average price of $3.04. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology Co. has a 12 month low of $1.53 and a 12 month high of $6.68.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.